In:
Arthritis und Rheuma, Georg Thieme Verlag KG, Vol. 42, No. 04 ( 2022-09), p. 236-240
Abstract:
The type 1 interferonopathies comprise a group of rare, genetically and phenotypically heterogeneous diseases characterized by a constitutive activation of type I interferon that is caused by a dysfunction of the innate immune system. The broad and variable clinical spectrum is characterized by the co-occurrence of autoinflammation, autoimmunity and immunodeficiency. Most commonly, pertubations in the metabolism or sensing of nucleic acids are responsible for the pathological constitutive activation of the type I IFN axis with harmful consequences for the host organism. Janus kinase inhibitors may provide an effective therapeutical option.
Type of Medium:
Online Resource
ISSN:
0176-5167
,
2567-5753
Language:
German
Publisher:
Georg Thieme Verlag KG
Publication Date:
2022
Permalink